VREX — Varex Imaging Corporation stock price, charts and financials

QT82Varex Imaging Corporation

Varex Imaging Corporation (NASDAQ: VREX) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
18.49
-0.05-0.27%
VREXQT82Varex Imaging Corporation·NASDAQ
18.49-0.27%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E35.22EPS (ttm)0.53Insider Own2.54%Shs Outstand42.10MPerf Week0.16%
Market Cap778.43MForward P/E17.28EPS next Y1.07Insider Trans-12.89%Shs Float41.40MPerf Month0.16%
Enterprise Value1.05BPEG0.21EPS next Q0.33Inst Own-Short Float3.03%Perf Quarter75.59%
Income22.11MP/S0.90EPS this Y61.54%Inst Trans-Short Ratio1.63Perf Half Y66.73%
Sales865.03MP/B1.57EPS next Y27.38%ROA2.01%Short Interest1.25MPerf YTD58.71%
Book/sh-P/C68.89EPS next 5Y31.35%ROE4.60%52W High18.63 -0.75%Perf Year59.40%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC6.41%52W Low9.09 103.41%Perf 3Y0.16%
Dividend Est.-EV/EBITDA12.12Sales past 3/5Y-0.55% 2.74%Gross Margin34.32%Volatility0.23% 0.24%Perf 5Y-35.19%
Dividend TTM-EV/Sales1.22EPS Y/Y TTM144.44%Oper. Margin8.35%ATR (14)0.15Perf 10Y-
Dividend Ex-Date-Quick Ratio1.53Sales Y/Y TTM6.78%Profit Margin2.55%RSI (14)83.46Recom2.71
Dividend Gr. 3/5Y-Current Ratio3.38EPS Q/Q72.22%SMA200.00%Beta0.97Target Price14.50
Payout0.00%Debt/Eq0.75Sales Q/Q3.94%SMA5019.91%Rel Volume0.98Prev Close18.54
Employees2,500LT Debt/Eq0.81EarningsNov 17SMA20046.12%Avg Volume853.20KPrice18.49
IPO DateJan 23, 2017Option/ShortYes / YesEPS/Sales Surpr.47.58% -2.32%Net Debt/EBITDA3.16Volume834,414Change-0.27%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-17-26DowngradeCJS SecuritiesOutperformMarket Perform
Aug-11-26DowngradeOppenheimerOutperformPerform
Aug-10-26DowngradeSidoti & Co.BuyNeutral
Feb-02-26ReiteratedJefferiesHold$17$15
May-28-24ReiteratedJefferiesHold$17
Feb-05-21UpgradeOppenheimerPerformOutperform
Aug-13-20DowngradeOppenheimerOutperformPerform
May-13-20DowngradeJP MorganOverweightNeutral
Mar-25-20UpgradeJP MorganNeutralOverweight
Feb-12-20DowngradeJefferiesBuyHold
Latest News· Times ET
Sep-16-26
Sep-12-26
Sep-05-26
Sep-01-26
Aug-28-26
Aug-24-26
Aug-23-26
Aug-15-26
Aug-12-26
Aug-11-26
Aug-10-26
Company

Varex Imaging Corporation (VREX) specializes in the development and production of X-ray imaging components. Its operations are divided into two primary divisions: Medical and Industrial. Within the Medical segment, Varex provides a comprehensive range of X-ray imaging components. These include essential hardware like X-ray tubes, digital detectors, and high-voltage connectors, alongside sophisticated software solutions for image processing, 3D reconstruction, and computer-aided diagnostics. The segment also supplies critical ancillary devices such as collimators, generators, and automatic exposure control mechanisms. These medical products serve a wide spectrum of applications, from general diagnostic imaging like radiography and fluoroscopy, to specialized areas such as mammography, computed tomography (CT), cardiac procedures, dental imaging, and surgical applications. They are also vital for radiation therapy, oncology, and advanced computer-aided detection systems. The Industrial segment focuses on providing X-ray technology for security and industrial inspection. Its offerings include Linatron X-ray accelerators, X-ray tubes, digital detectors, and high-voltage connectors. These components are crucial for diverse applications such as airport security scanning, cargo screening at border crossings, and nondestructive testing across various industries. Varex distributes its products through multiple channels, including direct sales to end-users, partnerships with imaging system Original Equipment Manufacturers (OEMs), independent service providers, and a network of distributors. With a significant global footprint, the company maintains operations across North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Established in 2016, Varex Imaging Corporation is headquartered in Salt Lake City, Utah.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
10/3/2025
FY 2024
9/27/2024
FY 2023
9/29/2023
FY 2022
9/30/2022
FY 2021
10/1/2021
FY 2020
10/2/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue866845811
Cost of Goods Sold Incl. D&A568554554
Gross Profit298291257
Selling, General and Administrative Excl. Other134133138
Research and Development919187
Other Operating Expense-1940
Operating Income72-2832
Interest Expense393631
Unusual Expense
Non-Operating Income (Expense)-644
Net Income Before Taxes28-595
Income Taxes51152
Consolidated Net Income22-70-48
Net Income From Continuing Operations22-70-47
Net Income22-70-48
EPS (Recurring)0.52-1.70-1.17
EPS (Basic, Before Extraordinaries)0.52-1.70-1.17
EPS (Diluted)0.52-1.70-1.17
EBITDA88463
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
35.56
Price To Sales Ratio0.900.580.60
Gross Margin34.4134.4431.69
Operating Margin8.31-3.313.95
Net Margin2.54-8.28-5.92
Shares Outstanding424141
Market Capitalization777490489
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$20.32$16.55$12.77$8.99$5.22 Close Price0.00M0.64M1.28M1.91M2.55MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kunkel Jay K.DirectorSep 14 '26Sale18.488,121150,07615,329Sep 15
Maheshwari ShubhamChief Financial OfficerSep 11 '26Sale18.46130,0002,400,060139,972Sep 15
Maheshwari ShubhamChief Financial OfficerSep 11 '26Option Exercise13.61160,9442,190,448269,972Sep 15
Aranki Karen LChief Human Resources OfficerAug 14 '26Option Exercise0.003,97408,893Aug 18
Kunkel Jay K.DirectorMar 20 '26Sale11.144,51050,24123,450Mar 23
Kunkel Jay K.DirectorFeb 09 '26Option Exercise0.008,483027,960Feb 10
GUERTIN TIMOTHY EDirectorFeb 09 '26Option Exercise0.008,483026,777Feb 09
Chertoff Jocelyn DDirectorFeb 09 '26Option Exercise0.008,483042,194Feb 09
Rosebrough Walter M JrDirectorFeb 09 '26Option Exercise0.0010,339052,654Feb 09
Bardwell KathleenDirectorFeb 09 '26Option Exercise0.008,483012,102Feb 09
TSINGOS CHRISTINE ADirectorFeb 09 '26Option Exercise0.008,483042,655Feb 09
Jonaitis Mark S.SVP and GM, X-Ray SourcesDec 10 '25Option Exercise0.0012,599082,867Dec 12
Hartmann AndrewSVP and GM, DetectorsDec 10 '25Option Exercise0.0012,599039,818Dec 12
SANYAL SUNNYPresident and CEODec 10 '25Option Exercise0.0074,2650264,458Dec 12
Aranki Karen LChief Human Resources OfficerDec 10 '25Option Exercise0.006,66506,842Dec 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.